Does Cardarine Actually Cause Cancer?
Most people who research cardarine walk away with one of two conclusions: that it causes cancer, or that the cancer studies used doses so extreme they mean nothing for a human taking 10 milligrams. Neither of those conclusions is quite right, and understanding why requires actually looking at what the receptor does and what the studies found.
Cardarine is not a SARM. It works through something called a PPARdelta agonist mechanism, which means it binds to a receptor inside your cells called PPARdelta, and that receptor controls which genes get switched on for fat burning and mitochondrial development. When cardarine activates that receptor, your body shifts its fuel preference away from glucose and toward stored fat, which is why it became interesting to researchers and athletes alike. The receptor itself is real, the metabolic effects are real, and the cancer concern is also real.
GlaxoSmithKline ran a two-year carcinogenicity study in rats, published in abstract form in 2009, and what they found ended the drug's development entirely. Two years is essentially the full adult life of a rat, which by body surface area scaling maps to roughly 60 years of daily human exposure. At every dose tested, rats developed tumors across multiple organ systems: the liver, bladder, stomach, thyroid, tongue, skin, and reproductive organs. That is not one tumor type in one organ. That is a multi-organ signal, which in toxicology is a significantly more concerning pattern than a localized finding. They then ran the same protocol in mice and got the same result. Two different species, same multi-organ cancer signal, every dose level.
That last part is the part that gets glossed over in most discussions.
The common rebuttal to the cancer concern is that the doses were far higher than what people actually use, and that part is technically true. Using the FDA's preferred body surface area conversion method for translating animal doses to human equivalents, the lowest dose that produced tumors in female rats works out to approximately 39 milligrams per day for a 175-pound person. In male rats, that number comes out to around 64 milligrams. People using cardarine are typically taking 10 to 20 milligrams. So there is a gap, and the gap is real.
But the gap is two to six times, depending on sex and which dose you compare against. In pharmaceutical development, the standard safety margin required before a drug moves forward is a ten-fold gap between the lowest observed effect level and the therapeutic dose. Cardarine does not come close to that threshold. And more importantly, the researchers never found a dose where tumors did not appear. There was no clean lower bound. There was no dose that produced the metabolic benefits without also producing the carcinogenic signal, which is precisely why GSK walked away from the compound entirely.
This is where the mechanism gets more complicated, and where understanding the receptor itself matters.
Exercise also activates PPARdelta. Your body uses the same receptor to shift toward fat oxidation during sustained aerobic work, and nobody is arguing that exercise causes cancer. So the obvious question is what is different about cardarine activating that receptor versus exercise activating it.
The answer appears to involve something called AMPK, which is a separate cellular energy sensor that gets activated during exercise alongside PPARdelta. Research published in the Journal of Biological Chemistry in 2021 showed that AMPK phosphorylates PPARdelta at a specific location, serine 50, and that phosphorylation acts like a molecular brake on the pro-tumorigenic transcriptional programs that PPARdelta can otherwise drive. In other words, exercise turns on the receptor but also activates a mechanism that suppresses the cancer-promoting downstream effects. Cardarine activates the receptor without necessarily triggering that same brake. The metabolic benefit and the carcinogenic risk appear to come from the same activation event, and exercise may separate them in a way that pharmacological activation does not.
That distinction is probably the most important thing to understand about cardarine's risk profile, because it explains why the cancer signal is not simply a function of dose but of mechanism.
The only human trial with cardarine followed 268 subjects taking up to 10 milligrams per day for 12 weeks and found no serious adverse events. That study, published in Arteriosclerosis, Thrombosis, and Vascular Biology in 2012, is sometimes cited as reassuring evidence. But 12 weeks is not a meaningful window for evaluating cancer risk. Carcinogenesis operates over years and decades, not months, and a short-term trial with a safety endpoint of adverse events is simply not designed to detect what the rat and mouse studies were measuring.
No study has tested cardarine at typical human doses, for typical cycle lengths, in healthy humans, with cancer as a primary endpoint. That study will almost certainly never exist because no pharmaceutical company will fund it and no ethics board would approve deliberately exposing people to a compound with this signal in animals.
That is not a gap that will be filled with more research. It is a permanent feature of the risk calculus.
If you have a personal or family history of cancer, or any known oncological risk factors, there is no version of this data that supports using cardarine. If you do not, you are still making a decision inside a genuine and probably permanent data gap, with animal evidence suggesting carcinogenicity across every dose tested and a mechanistic explanation for why the effect might not simply disappear at lower exposures.
The framing of "the doses were too high to matter" was never supported by the actual findings. The researchers were looking for a safe dose and did not find one.
References
- Geiger LE, Dunsford WS, Lewis DJ, Brennan C, Liu KC, Newsholme SJ 2009. Rat two-year carcinogenicity study with GW501516. Society of Toxicology 48th Annual Meeting, Abstract #895. Multi-organ tumors at all dose levels in Han Wistar rats including liver, bladder, stomach, thyroid, tongue, skin, and reproductive organs. Source
- Newsholme SJ, Dunsford WS, et al. 2009. Mouse two-year carcinogenicity study with GW501516. Society of Toxicology 48th Annual Meeting. Multi-organ tumor signal confirmed in mice, consistent with rat findings. Source
- Ding Y, et al. 2021. AMPK phosphorylates PPARdelta at Serine 50, suppressing pro-tumorigenic transcriptional programs while preserving metabolic benefits. Journal of Biological Chemistry, 297:100954. Source
- Reagan-Shaw S, Nihal M, Ahmad N 2008. Dose translation from animal to human studies revisited. FASEB Journal, 223:659-661. FDA-preferred body surface area normalization method for interspecies dose conversion. Source
- Olson EJ, Pearce GL, Jones NP, Sprecher DL 2012. Human RCT, 268 subjects, up to 10 mg/day for 12 weeks. No serious adverse events but far too short for cancer assessment. Arteriosclerosis, Thrombosis, and Vascular Biology, 329:2289-2294. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.